KIORA PHARMACEUTICALS INC — Director's Dealing 2021

Jul 29, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: EYEGATE PHARMACEUTICALS INC (EYEG)
CIK: 0001372514
Period of Report: 2021-07-27

Reporting Person: ARMISTICE CAPITAL, LLC (Director, 10% Owner)
Reporting Person: Armistice Capital Master Fund Ltd. (Director, 10% Owner)
Reporting Person: Boyd Steven (Director, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-07-27	Common Stock	C	852500	$4.80	Acquired	4199101	Indirect
2021-07-27	Common Stock	S	73101	$7.0602	Disposed	4126000	Indirect
2021-07-27	Common Stock	S	461797	$6.4549	Disposed	3664203	Indirect
2021-07-27	Common Stock	S	729114	$5.4397	Disposed	2935089	Indirect
2021-07-27	Common Stock	S	532069	$4.5877	Disposed	2403020	Indirect
2021-07-27	Common Stock	S	581614	$3.799	Disposed	1821406	Indirect
2021-07-28	Common Stock	S	375443	$3.2831	Disposed	1445963	Indirect
2021-07-29	Common Stock	S	400000	$3.00	Disposed	1045963	Indirect

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-07-27	Series C Convertible Preferred Stock	$4.80	C	4092	Disposed		Common Stock (852500)	Indirect

Footnotes

F1: The reported securities of EyeGate Pharmaceuticals, Inc. (the "Issuer") are directly held by Armistice Capital Master Fund Ltd., a Cayman Islands exempted company (the "Master Fund"), and may be deemed to be indirectly beneficially owned by: (i) Armistice Capital, LLC ("Armistice Capital"), as the investment manager of the Master Fund; and (ii) Steven Boyd, as the Managing Member of Armistice Capital ("Mr. Boyd", and collectively with the Master Fund and Armistice Capital, the "Reporting Persons"). Each of Armistice Capital and Mr. Boyd disclaim beneficial ownership of the reported securities except to the extent of their respective pecuniary interests therein, and this report shall not be deemed an admission that either of them are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.

F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $7.002 to $7.1559, inclusive. The reporting persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (4), (5), (6), (7), (8) and (9) to this Form 4.

F3: The Series C Convertible Preferred Stock has no expiration date and was convertible at any time at the option of the Master Fund.

F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $6.0052 to $6.9970, inclusive.

F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $5.1066 to $5.9464, inclusive.

F6: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.0011 to $4.9908, inclusive.

F7: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.5852 to $3.9402, inclusive.

F8: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $3.1713 to $3.4093, inclusive.

F9: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $2.85 to $3.24, inclusive.